Biological Information
Background Information:
Inducible nitric oxide synthase (iNOS) is a member of a growing family of enzymes that catalyze the conversion of L-arginine to citrulline and nitric oxide. Like other NOS isoforms, iNOS requires NADPH, FAD and terahydrobiopterin. From diabetes to hypertension, cancer to drug addiction, stroke to intestinal motility, memory and learning disorders to septic shock, sunburn to anorexia, male impotence to tuberculosis, there is probably no pathological condition where nitric oxide does not play an important role.
Family:
Nitrogen Metabolism
Sub Family:
Nitric Oxide Synthase
Class:
L-Arginine Turnover
Protein Name:
iNOS
Uniprot Number:
P35228
Gene Name:
NOS2
Gene ID:
4843
Gene Aliases:
iNOS|NOS|HEP-NOS
Accession Number:
NM_001313921
Organism:
Mouse
Construct Details:
Full Length, Recombinant
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
Spectrophotometry
Measured Response:
Absorbance
Testing Information
Procedure Summary:
Mouse recombinant iNOS expressed in E. coli cells is used. Test compound and/or vehicle are combined with 1.5 U/ml‡ of enzyme in Tris buffer pH 8.0. The reaction is initiated by addition of 0.1 mM L-Arginine for another 120 minute incubation period. Add Griess reagent and read plate on a spectrophotometer at 545 nm. Compounds are screened at 10 μM.
Substrate:
100 µM L-Arginine
Incubation:
120 min at 37°C
Control Inhibitor:
AMT
Criteria For Significance:
≥ 50 of max stimulation or inhibition
Test Concentration / Dose:
Suggested concentration for initial testing is 10 uM
Test Sample Requirements:
Minimum for 1) Screen: 25 μl of 10 mM stock -OR- 1 mg (pre-weighed). 2) Dose Response: 60 μl of 10 mM stock -OR- 1 mg (pre-weighed).
Minimum Order Quantity:
2
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS